You are here: Home » Companies » News
Business Standard

Strides' arm to set up facility in Malaysia for Rs 360 crore

Construction and fit-out of facility likely to be completed in 24 mths, commercial operations targeted to begin mid-2017

BS Reporter  |  Bengaluru 

Stelis Biopharma today announced the ground-breaking for construction of its customised, multi-product, biopharmaceutical manufacturing facility at Bio-Xcell Biotechnology Park in Nusajaya, Johor, Malaysia's park and ecosystem for industrial and healthcare biotechnology.

Stelis Biopharma, a wholly-owned subsidiary of Strides Arcolab Limited and Bio-XCell had previously announced the signing of a Build and Lease agreement with Bio-XCell for the construction of the building and part of the equipment of Stelis Biopharma's 140,000 sq. feet Biologics facility, for a total project investment amount of RM201 million. ($60 million or around Rs 360 crore), the company said in a statement.

The construction and fit-out of the facility is expected to be completed in 24 months and commercial operations are targeted to begin mid-2017at Bio-XCell Park. The facility will incorporate 'next-gen' single-use bio-processing technology with both mammalian and microbial manufacturing suites.

When complete, it will be one of the few Regulated Market approvable facilities in the Region with end-to-end capability including sterile fill-finish across all formats.

The facility will also house an R&D unit to conduct scale-up and process development studies.

Stelis Biopharma (Malaysia) Sdn. Bhd., the Strides subsidiary constructing this facility, will manufacture and commercialise its internal and partnered pipeline of bio-pharmaceuticals as well as cater to the demand for high-quality contract manufacturing and clinical supplies.

At peak operations, the facility will employ 180 people in R&D, Manufacturing, QA/QC, Analytical and Regulatory.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, December 03 2014. 19:48 IST